Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment

Rita Paniccia, Emilia Antonucci, Anna Maria Gori, Rossella Marcucci, Serena Poli, Eloisa Romano, Serafina Valente, Cristina Giglioli, Sandra Fedi, Gian Franco Gensini, Rosanna Abbate, Domenico Prisco

Research output: Contribution to journalArticle

Abstract

Patients with coronary artery disease (CAD) receiving aspirin therapy with a residual platelet reactivity (RPR) may be at increased risk of ischemic vascular events. Point-of-care (POC) methods PFA-100 (Dade-Behring, Marburg, Germany) and VerifyNow (Accumetrics, San Diego, CA) assays have been suggested as rapid tools to evaluate RPR. We compared PFA-100 closure times by collagen/epinephrine and VerifyNow Aspirin assays with light transmission aggregation (LTA) induced by 1 mmol/L of arachidonic acid in 484 patients with CAD undergoing percutaneous coronary intervention and receiving dual antiplatelet therapy. RPR was detected in 30.0% of patients by LTA, in 32.4% by PFA-100, and in 14.3% by VerifyNow. Significant correlations were found among 3 methods (all P <.0001). In relation to the presence or absence of RPR by LTA and PFA-100, by LTA and VerifyNow, and by PFA-100 and VerifyNow, samples were significantly concordant (all P <.0001). Assuming LTA as the reference method, PFA-100 and VerifyNow showed sensitivity of 62.1% and 39.3% and specificity of 80.2% and 96.4%, respectively. The cutoff values for POC methods need to be defined for clinical use.

Original languageEnglish
Pages (from-to)143-149
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume128
Issue number1
DOIs
Publication statusPublished - Jul 2007

Keywords

  • Aggregation
  • Aspirin
  • Platelet
  • Point-of-care testing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment'. Together they form a unique fingerprint.

  • Cite this

    Paniccia, R., Antonucci, E., Gori, A. M., Marcucci, R., Poli, S., Romano, E., Valente, S., Giglioli, C., Fedi, S., Gensini, G. F., Abbate, R., & Prisco, D. (2007). Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. American Journal of Clinical Pathology, 128(1), 143-149. https://doi.org/10.1309/0G1PEJ00J8KP8357